Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04914897
Title A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sanofi
Indications

malignant pleural mesothelioma

lung non-small cell carcinoma

lung non-squamous non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707

Pembrolizumab + THOR-707

Nab-paclitaxel + Pembrolizumab + THOR-707

Cisplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP


No variant requirements are available.